Trials / Completed
CompletedNCT00165737
Donepezil Hydrochloride (E2020) in Dementia Associated With Cerebrovascular Disease
A 24-Week, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Evaluation of the Efficacy, Safety and Tolerability of Donepezil Hydrochloride (E2020) in Patients With Dementia Associated With Cerebrovascular Disease
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 974 (actual)
- Sponsor
- Eisai Inc. · Industry
- Sex
- All
- Age
- 41 Years
- Healthy volunteers
- Not accepted
Summary
Twenty-four week, prospective, randomized, double-blind, placebo-controlled, parallel-group study.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Donepezil Hydrochloride |
Timeline
- Start date
- 2003-03-01
- Primary completion
- 2005-08-01
- Completion
- 2006-06-01
- First posted
- 2005-09-14
- Last updated
- 2011-04-01
Locations
5 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00165737. Inclusion in this directory is not an endorsement.